AURKA and prostate neoplasm: MLN8237 is a selective AURKA inhibitor which is a potential therapeutic agent for B-cell and T-cell non-Hodgkin lymphoma, breast, lung and prostate tumors, neuroblastoma and multiple myeloma15.